Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person25
Genprex, Inc.
Company
Genvor Inc
Company
GENESCO INC
Company
Genasys Inc.
Company
Gevo, Inc.
Company
Gentherm Inc
Company
Enpro Inc.
Company
GAP INC
Company
TREX CO INC
Company
CEMTREX INC
Company
WEX Inc.
Company
Gen Digital Inc.
Company
10x Genomics, Inc.
Company
TRex Bio, Inc.
Company
PRECIGEN, INC.
Company
GEE Group Inc.
Company
GEO GROUP INC
Company
GPGI, Inc.
Company
Inogen Inc
Company
Gogo Inc.
Company
GDEV Inc.
Company
GAIA, INC
Company
Opus Genetics, Inc.
Company
GENERAL MILLS INC
Company
Getaround, Inc
Company
Primary record5
Genprex, Inc. filed 8-K
Item 8.01 Other Events. On November 5, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing results from a translational analysis of patients treated with its lead drug candidate, Reqorsa® (
Genprex, Inc. filed 8-K
Item 8.01 Other Events. On November 4, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that new research identifying TROP2 expression as a potential predictive biomarker of response to
Genprex, Inc. filed 8-K
Item 8.01 Other Events. On October 28, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that research conducted under its sponsored research collaboration with Meharry Medical College wi
Genprex, Inc. filed 8-K
Item 8.01 Other Events. On October 21, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release highlighting new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor
Genprex, Inc. filed 8-K
Item 8.01 Other Events. On August 18, 2026, Genprex, Inc. ( Genprex or the Company ) issued a press release announcing it had entered into a development and manufacturing agreement with a leading U.S. based clinical and